RYR1 Antibody

What is RYR1 and why is it important in physiological research?

RYR1 (Ryanodine Receptor 1) is a major calcium channel protein primarily expressed in skeletal muscle that plays a critical role in excitation-contraction coupling. In humans, the canonical protein has 5038 amino acid residues with a molecular mass of 565.2 kDa, with up to three different isoforms reported . Beyond skeletal muscle, RYR1 is notably expressed in the cerebral cortex, cerebellum, and caudate regions of the brain . As a member of the Ryanodine receptor (TC 1.A.3.1) protein family, RYR1 functions to mediate calcium release from the sarcoplasmic reticulum into the cytoplasm, triggering muscle contraction following depolarization of T-tubules . Its fundamental role in calcium signaling makes it a crucial target for investigating muscle physiology, neuromuscular disorders, and calcium homeostasis mechanisms.

What are the key structural and functional domains of RYR1 relevant to antibody targeting?

The RYR1 protein contains several functionally important domains that researchers should consider when selecting antibodies. The transmembrane region comprises two key domains: the pseudo voltage sensor domain and the pore-forming domain . These regions are critical for the calcium-conducting properties of the channel. When studying RYR1 mutations associated with conditions like malignant hyperthermia (MH), it's important to note that pathogenic variants often cluster in three distinct "hotspot" regions of the protein . Antibodies targeting specific domains should be selected based on research objectives—whether examining channel function, protein-protein interactions (particularly calstabin1 binding), or post-translational modifications like oxidation that can affect channel leak .

How do I select the appropriate RYR1 antibody for my specific research application?

When selecting RYR1 antibodies, consider:

Application compatibility: Different antibodies are optimized for specific techniques. For example:

• Western Blot applications: Cell Signaling Technology's RyR1 (D4E1) Rabbit mAb has been validated and cited in 19 publications .

• Immunofluorescence: Several antibodies including Proteintech's 26968-1-AP show good reactivity in IF-P applications .

• Immunohistochemistry: Some antibodies work well on specific tissues with recommended antigen retrieval methods (e.g., TE buffer pH 9.0 for Proteintech's antibody) .

Species reactivity: Verify cross-reactivity with your experimental model. RYR1 orthologs have been reported in mouse, rat, bovine, frog, chimpanzee, and chicken species . Many commercial antibodies are tested against human and mouse samples, with fewer validated for other species .

Epitope location: Consider which region of RYR1 you need to detect, especially when studying specific mutations or post-translational modifications in disease models such as RYR1-related myopathies (RYR1-RM) .

Validation data: Review published literature citing specific antibodies for your application of interest. Over 500 citations describe the use of RYR1 antibodies in research .

What are the optimal protocols for using RYR1 antibodies in immunohistochemistry of muscle tissue?

For optimal immunohistochemistry (IHC) of muscle tissue using RYR1 antibodies, follow these methodological guidelines:

Tissue preparation and fixation:

• Fresh frozen sections often provide better antigen preservation for RYR1 detection

• If using formalin-fixed paraffin-embedded (FFPE) tissues, limit fixation time to preserve epitope accessibility

Antigen retrieval:

• Use heat-induced epitope retrieval with TE buffer at pH 9.0 for optimal results with antibodies like Proteintech's 26968-1-AP

• As an alternative, citrate buffer at pH 6.0 may be used, though potentially with reduced sensitivity

Antibody concentration and incubation:

• Start with a dilution range of 1:50-1:500 as recommended by manufacturers

• Optimize through titration experiments for your specific tissue samples

• Incubate at 4°C overnight for maximal sensitivity or at room temperature for 1-2 hours

Detection system:

• Use a detection system compatible with the host species of your primary antibody

• For skeletal muscle, which shows high endogenous background, consider using polymer-based detection systems with minimal cross-reactivity

Controls:

• Always include positive control tissues known to express RYR1 (human skeletal muscle or cerebellum)

• Include negative controls by omitting primary antibody or using tissues from RYR1-knockout models if available

Remember that RYR1 detection works particularly well in mouse brain tissue, human cerebellum tissue, and human skeletal muscle tissue , providing good options for positive controls.

How can I optimize Western blot protocols for detecting RYR1 considering its large molecular weight?

Detecting RYR1 by Western blot presents unique challenges due to its large molecular weight (565 kDa). Follow these specialized protocols for optimal results:

Sample preparation:

• Use fresh samples whenever possible

• Extract proteins with buffers containing protease inhibitors and phosphatase inhibitors

• Add reducing agents like DTT or β-mercaptoethanol to fully denature the protein

Gel electrophoresis:

• Use low percentage (3-5%) SDS-PAGE gels or gradient gels (3-8% or 4-12%)

• Consider commercial pre-cast gels designed for high molecular weight proteins

• Run at lower voltage (60-80V) for extended periods to achieve better separation

Transfer optimization:

• Use wet transfer systems rather than semi-dry for proteins >200 kDa

• Transfer at low voltage (25-30V) overnight at 4°C

• Use transfer buffers with reduced methanol (5-10%) and added SDS (0.1%)

• Consider using PVDF membranes with 0.45 μm pore size rather than 0.22 μm

Antibody incubation:

• Block thoroughly (3-5% BSA or milk in TBST) for at least 1 hour

• Use antibodies specifically validated for Western blot applications, such as Cell Signaling Technology's RyR1 (D4E1) Rabbit mAb

• Extend primary antibody incubation time (overnight at 4°C)

• Use longer washing steps to reduce background

Detection considerations:

• Use enhanced chemiluminescence with extended exposure times

• Consider using signal enhancers for large molecular weight proteins

This optimized protocol addresses the specific challenges associated with detecting the extremely large RYR1 protein while minimizing degradation and ensuring specific detection.

What are the considerations for co-immunoprecipitation experiments involving RYR1 and its binding partners?

Co-immunoprecipitation (Co-IP) of RYR1 and its binding partners requires careful consideration of the protein's size, complex formation, and dynamic interactions:

Experimental design considerations:

• Select detergents carefully to maintain protein-protein interactions while solubilizing RYR1 (typically 1% CHAPS or 0.5-1% digitonin work better than stronger detergents)

• Use crosslinking reagents for transient interactions

• Include calcium chelators or calcium at physiological concentrations depending on whether you want to study calcium-dependent interactions

Specific binding partners:

• For studying RYR1-calstabin1 binding, which is frequently disrupted in RYR1-related myopathies, ensure your lysis conditions preserve this interaction

• Include controls for oxidative conditions, as RYR1 oxidation reduces calstabin1 binding and promotes channel leak

Validation approaches:

• Perform reciprocal IPs (using antibodies against both RYR1 and the binding partner)

• Include negative controls using non-specific IgG

• Validate interactions with multiple techniques (e.g., proximity ligation assay)

Detection methods:

• When probing western blots of IP samples, use clean detecting antibodies that don't cross-react with the IP antibody

• Consider stripping and reprobing membranes to detect multiple interacting proteins

Research has demonstrated that co-immunoprecipitation followed by immunoblotting is effective for showing RYR1 channel oxidation states and binding to regulatory proteins like calstabin1, with diseased samples showing reduced RyR1-calstabin1 binding ranging from 10-25% of control values .

How can RYR1 antibodies be used to distinguish between pathogenic and benign RYR1 variants in myopathy research?

RYR1 antibodies play a crucial role in functional validation of RYR1 variants identified in genetic testing. This approach is particularly valuable given that large variant datasets show most reported pathogenic variants localize to three distinct hotspot regions, while benign variants from gnomAD distribute more evenly across the channel .

Methodological approach:

• Immunoprecipitation and protein modification assessment: Use RYR1 antibodies to immunoprecipitate the channel complex from patient muscle biopsies or recombinant expression systems. Analysis of post-translational modifications like oxidation can provide evidence of channel dysfunction. Studies have shown that pathogenic RYR1 variants consistently show increased channel oxidation .

• Protein-protein interaction analysis: The binding of calstabin1 (FKBP12) to RYR1 is a critical regulator of channel function. Co-immunoprecipitation with immunoblotting has demonstrated that pathogenic RYR1 variants show reduced RyR1-calstabin1 binding (10-25% of control levels) regardless of variant location .

• Recombinant expression studies: For variants of uncertain significance, express recombinant RYR1 constructs containing the variant in HEK293-T cells and use antibodies to confirm expression before functional calcium release assays. This approach successfully demonstrated that p.Asn2342Ser results in a hypersensitive channel while p.Trp661* results in a non-functional channel .

• Structure-function correlation: Recent research has developed a method for assigning pathogenicity probabilities to RYR1 variants based on 3D co-localization of known pathogenic variants, providing a computational approach that complements antibody-based functional studies .

For optimal results, combine antibody-based biochemical characterization with functional calcium release assays, as demonstrated in studies of variants like p.Asn2342Ser and p.Pro816Leu, which were shown to produce hypersensitive channels at different concentrations of RyR1 agonists like 4-chloro-m-cresol (4-CmC) .

What strategies can be employed to study RYR1 post-translational modifications using specific antibodies?

Studying post-translational modifications (PTMs) of RYR1 is essential for understanding channel regulation in normal physiology and disease states. Several antibody-based strategies can be employed:

Modification-specific antibodies:

• Use antibodies that specifically recognize phosphorylated, oxidized, or nitrosylated RYR1

• For oxidation studies, antibodies detecting DNP (dinitrophenyl) groups after derivatization of carbonylated proteins can identify oxidative modifications

Sequential immunoprecipitation approach:

• Immunoprecipitate total RYR1 using a general RYR1 antibody

• Probe the immunoprecipitated material with modification-specific antibodies

• Alternatively, use modification-specific antibodies for the initial immunoprecipitation

• Quantify the ratio of modified to total RYR1

Proximity ligation assays:

• This technique can detect PTMs in situ with high sensitivity

• Combine a general RYR1 antibody with a modification-specific antibody

• Positive signals indicate the proximity of the two epitopes, confirming the presence of the modification on RYR1

Mass spectrometry validation:

• Use antibody-based enrichment of RYR1 followed by mass spectrometry

• This approach can identify novel modification sites and quantify modification stoichiometry

Research has shown that RYR1 oxidation status correlates with channel dysfunction in RYR1-related myopathies, with patient samples showing increased channel oxidation compared to controls . This oxidation leads to decreased calstabin1 binding and promotes calcium leak, providing a potential therapeutic target for RYR1-related disorders.

How can RYR1 antibodies be utilized in studying the therapeutic effects of Rycal compounds in RYR1-related myopathies?

RYR1 antibodies provide crucial tools for evaluating the mechanism of action and efficacy of Rycal compounds, which stabilize RYR1-calstabin1 binding and reduce pathological calcium leak:

Mechanistic studies:

• Use co-immunoprecipitation with RYR1 antibodies followed by immunoblotting for calstabin1 to quantify the effect of Rycals (like S107) on enhancing RyR1-calstabin1 binding

• Compare samples before and after Rycal treatment to measure restoration of normal binding levels

• Research has demonstrated that Rycals can be effective RyR stabilizing molecules for treating RYR1-RM

Ex vivo tissue studies:

• In muscle biopsies from affected individuals, use immunofluorescence with RYR1 antibodies to evaluate:

  • RYR1 localization and distribution

  • Co-localization with calstabin1 before and after Rycal treatment

  • Changes in calcium handling proteins that may be secondarily affected

Oxidation status assessment:

• Since RYR1 oxidation causes reduction in calstabin1 binding and promotes channel leak, use oxidation-specific detection methods in conjunction with RYR1 antibodies

• Monitor changes in oxidation status following Rycal treatment

• Studies have demonstrated consistent increases in channel oxidation in patient samples relative to controls

Translational biomarker development:

• Use quantitative assessment of RYR1-calstabin1 binding or RYR1 oxidation state as potential biomarkers for clinical trials

• These parameters can help select patients most likely to respond to Rycals and monitor treatment efficacy

The use of RYR1 antibodies in these contexts has provided the rationale for clinical trials testing Rycals in RYR1-RM affected individuals , demonstrating the translational value of antibody-based research in therapeutic development.

What are the common technical challenges when using RYR1 antibodies and how can they be addressed?

Challenge 1: Low signal intensity in Western blots

• Cause: Inefficient transfer of high molecular weight RYR1 (565 kDa)

• Solution: Use specialized transfer conditions for large proteins (low voltage transfer overnight at 4°C, reduced methanol in transfer buffer, addition of 0.1% SDS)

• Alternative approach: Consider using slot or dot blots for simple presence/absence determination

Challenge 2: Non-specific background in immunohistochemistry

• Cause: Cross-reactivity with other ryanodine receptor isoforms (RYR2/RYR3)

• Solution: Validate antibody specificity using tissues with known expression patterns (e.g., skeletal muscle primarily expresses RYR1)

• Alternative approach: Use antigen retrieval with TE buffer pH 9.0 as recommended for antibodies like Proteintech's 26968-1-AP

Challenge 3: Inconsistent immunoprecipitation results

• Cause: Complex formation with other proteins or inadequate solubilization

• Solution: Optimize detergent concentration and lysis conditions to maintain protein-protein interactions while ensuring adequate solubilization

• Alternative approach: Consider crosslinking strategies before lysis to stabilize protein complexes

Challenge 4: Epitope masking in fixed tissues

• Cause: Fixation can mask epitopes, particularly in FFPE samples

• Solution: Test multiple antigen retrieval methods; alternatives include citrate buffer pH 6.0 if TE buffer pH 9.0 is ineffective

• Alternative approach: When possible, use fresh frozen sections for better epitope preservation

Challenge 5: Detecting specific isoforms

• Cause: Up to three different isoforms have been reported for RYR1

• Solution: Select antibodies raised against regions that differ between isoforms

• Alternative approach: Combine antibody detection with molecular techniques like RT-PCR to confirm isoform expression

For all applications, it is recommended to titrate antibodies in each testing system to obtain optimal results, as sensitivity can be sample-dependent .

How can researchers validate the specificity of RYR1 antibodies in their experimental systems?

Validating RYR1 antibody specificity is critical for reliable experimental results. Implement these validation strategies:

Genetic validation approaches:

• Knockout/knockdown controls: Use tissues or cells from RYR1 knockout models or RYR1-depleted cells via siRNA/shRNA

• Overexpression systems: Test antibody reactivity against recombinant RYR1 expressed in heterologous systems like HEK293-T cells

• Competitive blocking: Pre-incubate antibody with immunizing peptide before application to verify signal reduction

Cross-reactivity assessment:

• Isoform specificity: Test antibody against tissues with differential expression of RYR isoforms (skeletal muscle for RYR1, cardiac muscle for RYR2, brain for RYR3)

• Species cross-reactivity: Verify reactivity across species if using animal models by testing antibodies on human, mouse, and other relevant species tissues

Technical validation:

• Multiple antibody concordance: Use multiple antibodies targeting different RYR1 epitopes and confirm similar staining patterns

• Multiple technique concordance: Validate findings across different techniques (e.g., IF, WB, IHC)

• Molecular weight verification: Confirm that detected bands match the expected molecular weight of RYR1 (565 kDa)

Literature and database validation:

• Citation validation: Review publications citing specific antibodies; for instance, Cell Signaling Technology's RyR1 (D4E1) Rabbit mAb has 19 citations supporting its use in Western blot applications

• Antibody validation databases: Consult resources like Antibodypedia or the Antibody Registry

Experimental controls to include:

• Positive control tissues known to express RYR1 (e.g., human skeletal muscle, cerebellum)

• Negative control tissues where RYR1 expression is minimal or absent

• Technical negative controls (primary antibody omission)

How are RYR1 antibodies contributing to the understanding of RYR1-related myopathies and potential therapeutic approaches?

RYR1 antibodies have been instrumental in advancing our understanding of pathomechanisms and therapeutic targets for RYR1-related myopathies (RYR1-RM):

Characterization of pathogenic mechanisms:

• Antibody-based co-immunoprecipitation studies have revealed increased oxidation and reduced calstabin1 binding in RYR1 channels from affected individuals

• These biochemical changes were consistently observed regardless of variant location, suggesting a common pathomechanism of channel dysfunction

• For variants of uncertain significance (VUS), antibodies enable functional characterization through recombinant expression systems and calcium release assays

Development of predictive tools:

• Integration of antibody-based functional studies with structural information has led to methods for assigning pathogenicity probabilities to RYR1 variants based on 3D co-localization of known pathogenic variants

• This approach helps evaluate the expanding dataset of over 2200 suspected RYR1-RM affected individuals with 546 unique RYR1 variants

Therapeutic target identification:

• Antibody studies have validated the RyR1-calstabin1 interaction as a druggable target, providing the rationale for clinical trials testing Rycal compounds in RYR1-RM

• S107, a RyR stabilizing Rycal molecule, has emerged as a promising treatment based on its ability to restore normal channel function

Disease classification:

• Antibody-based profiling has helped distinguish between different RYR1-related disorders like central core disease (CCD), multimini-core disease (MmD), centronuclear myopathy (CNM), and malignant hyperthermia susceptibility

• This has improved diagnostic accuracy and prognostic information for patients

These advances highlight how antibody-based research continues to bridge the gap between genetic findings and therapeutic development for RYR1-related disorders.

What role do RYR1 antibodies play in investigating calcium dysregulation in other pathological conditions beyond myopathies?

RYR1 antibodies have expanded our understanding of calcium dysregulation in multiple pathological conditions beyond classical myopathies:

Neurological disorders:

• RYR1 is expressed in cerebral cortex, cerebellum, and caudate regions , making it relevant to neurological conditions

• Antibody-based studies have identified altered RYR1 expression or function in neurodegenerative diseases

• Immunofluorescence techniques using RYR1 antibodies in mouse brain and cerebellum tissue have helped map its neuroanatomical distribution and potential role in neuronal calcium signaling

Age-related muscle dysfunction:

• Antibody studies have revealed age-dependent changes in RYR1 oxidation status and calstabin1 binding

• These changes contribute to calcium leak and muscle weakness in aging

Metabolic disorders:

• RYR1 dysfunction has been implicated in insulin resistance and type 2 diabetes

• Antibody-based techniques have helped characterize RYR1 modifications in metabolic disease models

Cardiac pathologies:

• While RYR2 is the predominant cardiac isoform, RYR1 is also expressed in cardiac tissue

• RYR1 antibodies have helped differentiate the roles of different RyR isoforms in cardiac pathologies

Cancer research:

• Altered calcium signaling is a hallmark of many cancers

• RYR1 antibodies have been used to investigate its potential role in cancer cell proliferation and migration

Exercise physiology:

• Antibody-based studies have illuminated RYR1's role in normal muscle adaptation to exercise

• Post-translational modifications of RYR1 during exercise have been characterized using modification-specific antibodies

Methodologically, these investigations rely on techniques including immunohistochemistry (IHC), immunofluorescence (IF), western blotting (WB), and ELISA using RYR1 antibodies with validated reactivity across human and animal model tissues .

What are the emerging techniques combining RYR1 antibodies with advanced imaging or other methodologies?

Recent technological advances have expanded the capabilities of RYR1 antibody-based research:

Super-resolution microscopy applications:

• STORM/PALM imaging: Combines RYR1 antibodies with photo-switchable fluorophores to achieve nanoscale resolution of RYR1 clusters at the sarcoplasmic reticulum

• SIM (Structured Illumination Microscopy): Enables live-cell imaging of RYR1 distribution and dynamics with resolution beyond the diffraction limit

• These techniques have revealed previously undetectable details about RYR1 organization in triads and calcium release units

In situ proximity detection methods:

• Proximity Ligation Assay (PLA): Detects RYR1 interactions with regulatory proteins or post-translational modifications with high sensitivity

• FRET-based approaches: When combined with appropriate fluorophore-conjugated antibodies, allows real-time monitoring of protein-protein interactions

• These methods provide spatial information about RYR1 regulation in intact cells or tissues

Single-molecule techniques:

• Single-molecule pull-down: Uses RYR1 antibodies immobilized on surfaces to capture individual channel complexes for detailed biochemical analysis

• Single-particle tracking: Employs antibody fragments to track RYR1 mobility in living cells

Mass cytometry (CyTOF):

• Combines metal-conjugated RYR1 antibodies with mass spectrometry for high-dimensional analysis

• Allows simultaneous detection of multiple proteins and post-translational modifications in the RYR1 complex

3D tissue imaging approaches:

• CLARITY and tissue clearing: Compatible with RYR1 antibodies for whole-tissue 3D imaging

• Light-sheet microscopy: When used with appropriate antibodies, enables rapid 3D visualization of RYR1 distribution throughout intact muscle samples

• These approaches have improved understanding of the three-dimensional organization of calcium handling proteins in whole tissues

Cryo-electron microscopy integration:

• Combining structural information from cryo-EM with antibody epitope mapping

• This integration has advanced the understanding of how RYR1 variants affect channel structure and function

These emerging techniques are pushing the boundaries of RYR1 research by providing unprecedented resolution, sensitivity, and multi-dimensional information about this crucial calcium channel and its regulation in health and disease.